On Monday, Venture capital firm The Column Group agreed to acquire NGM Biopharmaceuticals Inc (NASDAQ:NGM) for $1.55/share in cash.
The Column Group is NGM Bio’s longest and largest stockholder, holding approximately 26% of NGM Bio’s outstanding shares.
NGM Bio stock is trading lower with a session volume of 1.9 million, compared to the average volume of 1.02 million, as per the data from Benzinga Pro.
The price per share corresponds to a total equity value of $135 million on a fully diluted basis and represents an 80% premium over the last trading day closing price (December 29, 2023) prior to NGM ...